Abstracts tagged "fibromyalgia"

Abstract Number: 1831 • ACR Convergence 2023
Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia
Tali Sahar¹, Amir Minerbi², maria Verner¹, sabrina Mitrovic³, yoram Shir¹, Gabrielle Page⁴ and mary-ann fitzcharles¹, ¹McGill University, Montreal, QC, Canada, ²Rambam Health Campus, Haifa, Israel, ³McGill University, Montréal-Ouest, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada
Background/Purpose: Fibromyalgia (FM) symptoms fluctuate, with exacerbation commonly associated with stressors. The COVID-19 pandemic was a cause of prolonged stress due to factors such as…
Abstract Number: 1189 • ACR Convergence 2023
Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis
Carly Conran¹, Larry Moreland², Andrew Clauw¹, Jennifer Seifert¹, Carson Keeter³, Craig Hogan¹ and Michael Dayton¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Denver, CO, ³University of Colorado, Aurora, CO

Background/Purpose: Chronic pain in patients with hip and knee osteoarthritis (OA) has been classically attributed to nociceptive pain pathways. Emerging evidence has demonstrated influence from…
Abstract Number: 1832 • ACR Convergence 2023
Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital
Miriam Kiyiapi, Omondi Oyoo, Peter Oyiro and Frederick Wangai, University of Nairobi, Nairobi, Kenya
Background/Purpose: Since its discovery in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) has ravaged the globe on an unprecedented scale. While…
Abstract Number: 1290 • ACR Convergence 2023
Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis
Katie McMenamin¹, Kristin Wipfler², Austin Wheeler³, Grant Cannon⁴, K Wysham⁵, Brian Sauer⁶, Bryant England³, Kaleb Michaud³, Ted R Mikuls⁷ and Joshua Baker⁸, ¹Boston University, Boston, MA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…
Abstract Number: 1833 • ACR Convergence 2023
Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores
Jeffrey Rosenfeld¹, Greta Linse², Sally Slipher², Candace Flint³, Annie Iserson³, Herbert Harris⁴, Jean Engels³, Gregory Sullivan⁵ and Seth Lederman⁶, ¹Tonix Pharmaceuticals, Chatham, NJ, ²Montana State University, Bozeman, MT, ³Tonix Pharmaceuticals, New York, NY, ⁴Tonix Pharmaceuticals, Chapel Hill, NC, ⁵Tonix Pharmaceuticals Inc, Chatham, NJ, ⁶Tonix Pharmaceuticals, South Dartmouth, MA
Background/Purpose: Fibromyalgia (FM) is characterized by widespread pain, non-restorative sleep, fatigue, and cognitive dysfunction. TNX-102 SL is a sublingual cyclobenzaprine tablet designed for daily use…
Abstract Number: 1421 • ACR Convergence 2023
Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)
Laura Coates¹, Carlo Selmi², Georg Schett³, Pascal Richette⁴, Felipe Julio Ramirez Garcia⁵, Wim Noël⁶, Emmanouil Rampakakis⁷, Miriam Zimmermann⁸, Mohamed Sharaf⁹ and Dennis McGonagle¹⁰, ¹University of Oxford, Oxford, United Kingdom, ²Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Lariboisière Hospital, Paris, France, ⁵Hospital Clínic, Barcelona, Spain, ⁶Janssen, Zemst, Belgium, ⁷JSS Medical Research, Saint-Laurent, QC, Canada, ⁸Janssen Pharmaceuticals, Zug, Switzerland, ⁹Immunology, Janssen MEA, Dubai, United Arab Emirates, ¹⁰Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom
Background/Purpose: Sustained minimal disease activity (MDA) is achieved by a minority of patients (pts) receiving biologics for psoriatic arthritis (PsA). Pt-reported MDA domains are less…
Abstract Number: 1834 • ACR Convergence 2023
Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort
Kelly Corbitt¹, Philip Carlucci², Brooke Cohen³, Mala Masson³, H Michael Belmont⁴, Amit Saxena⁵, Chung-E Tseng³, Jing Wang³, Kamil Barbour⁶, Jill Buyon⁷, Peter Izmirly² and Heather Gold³, ¹New York University, El Portal, FL, ²New York University School of Medicine, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, Rheumatology, New York, NY, ⁶Centers for Disease Control and Prevention, Atlanta, GA, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: SLE patients have a higher prevalence of fibromyalgia (FM) than the general population. FM symptoms, such as nociplastic pain and fatigue, are known to…
Abstract Number: 1575 • ACR Convergence 2023
Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study
Darpan Radheshyam Thakare, Upendra Rathore, Kritika Singh, Vikas Agarwal and Durga P Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India
Background/Purpose: Few studies have assessed patient-reported outcome measures in Takayasu arteritis (TAK), a rare large vessel vasculitis. We prospectively analysed fatigue and fibromyalgia in TAK…
Abstract Number: 1835 • ACR Convergence 2023
A Survey on Fibromyalgia-Related Knowledge Among Internal Medicine Residents
Summia Matin Afridi¹, Ahmad Raja² and Muhammad Daniyal³, ¹Albany Medical Center, Albany, NY, ²Mary Imogene Bassett Hospital, Evanston, IL, ³Mary Imogene Bassett Hospital, Cooperstown, NY
Background/Purpose: Fibromyalgia is a chronic pain syndrome that commonly presents with fatigue, widespread musculoskeletal pain, and sleep disturbances. Patients can also have accompanying somatic and…
Abstract Number: 1578 • ACR Convergence 2023
Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis
Alejandra Espinosa-Orantes¹, David Vera-Bustamante², Jessica Roldan Ortega³, Maria Mejia-Avila⁴, Jose Raul Molina⁵, Evelyn Aranda Cano⁵, Adriana Miguel-Alvarez⁵, Ismael Valenzuela⁵, Viridiana Del Río-Guerrero⁶, Paloma Rodriguez⁵, Mauricio Mora-Ramirez⁵, Nilda Espinola-Zavaleta⁴, Luis H Silveira-torre⁶, Angélica Vargas Guerrero⁷ and Laura A Martínez-Martínez⁸, ¹Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ²BENEMERITA UNIVERSIDAD AUTONOMA DE PUEBLA, Mexico City, Mexico, ³INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Mexico, ⁴Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Instituto Nacional de Cardiologia, Mexico City, Mexico, ⁶Instituto Nacional de Cardiología, Mexico City, Mexico, ⁷Instituto Nacional de Cardiología, Mexico City, Mexico, ⁸Universidad Nacional Autónoma de México - Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Takayasu arteritis (TAK) is a chronic, granulomatous large-vessel vasculitis. As TAK has a chronic course, higher frequency rates of anxiety and depression are reported…
Abstract Number: 1836 • ACR Convergence 2023
Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium
Jennifer Rogers¹, Megan Clowse² and Amanda Eudy³, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Raleigh, NC
Background/Purpose: Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are…
Abstract Number: 1609 • ACR Convergence 2023
Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study
Danilo Perretta¹, Daniele Mauro¹, flavia riccio¹, valentina marino¹, emma scoppetta², Francesco ciccia¹ and rosella tirri¹, ¹University of Campania - Luigi Vanvitelli, Naples, Italy, ²University of Salerno, Salerno, Italy
Background/Purpose: SARS-CoV-2 infection has been increasingly recognized for its potential neurological manifestations. Fibromyalgia (FM) patients, who already experience neuropathic pain, may be particularly vulnerable to…
Abstract Number: 1837 • ACR Convergence 2023
Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia
Irakli Tskhakaia¹, Pushti Khandwala¹ and Irene Tan², ¹Albert Einstein Medical Center Philadelphia, Philadelphia, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Suicide and depression represent a high burden of morbidity and mortality worldwide. It is well known that fibromyalgia (FM) is associated with mood and…
Abstract Number: 0263 • ACR Convergence 2022
DAS28 (disease Activity Score) Elevations in Patients with Rheumatoid Arthritis (RA) Who Have Comorbid Fibromyalgia Are Explained by Elevated Tender Joint Counts as Much as by Elevated Patient Global Assessment
Sandhya shri Kannayiram¹, Juan Schmukler², Nicola Goodson³ and Theodore Pincus², ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³University Hospital Aintree, Liverpool, United Kingdom
Background/Purpose: Several reports indicate that patient global assessment (PATGL) may elevate DAS28 (disease activity score 28) and/or other indices in patients with rheumatoid arthritis (RA),…
Abstract Number: 1908 • ACR Convergence 2022
Should Osteoarthritis Patients with Pain Scores More Than 8/10 Be Analyzed Separately or Excluded from Clinical Trial Protocols, as 72% Screen Positive for Fibromyalgia And/or Depression on a Multidimensional Health Assessment Questionnaire (MDHAQ)?
Juan Schmukler¹, Kathryn Gibson², Tengfei Li³, Joel Block¹ and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Sydney, Australia, ³Georgetown University, Washington, DC
Background/Purpose: Most osteoarthritis (OA) clinical trial protocols require a 0-10 pain visual numeric scale (VNS) or other quantitative pain score of 4/10 or more for…

« Previous Page
1
…
4
5
6
7
8
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].